Severe respiratory syncytial virus disease

Area of Science:

• Pediatrics
• Infectious Diseases
• Pulmonology

Background:

• Respiratory syncytial virus (RSV) poses a substantial global health burden, particularly affecting infants, the elderly, and immunocompromised individuals.
• Severe RSV disease disproportionately impacts hospitalized adults with comorbidities, necessitating intensive care.
• Current management relies heavily on supportive care, highlighting the need for advanced therapeutic strategies.

Purpose of the Study:

• To review the current understanding of respiratory syncytial virus (RSV) disease burden, risk factors, and management strategies.
• To discuss advancements in supportive care for severe RSV infections, including ventilation techniques.
• To explore the challenges and future directions in treating RSV, including bacterial co-infections and novel therapeutics.

Main Methods:

• Literature review of existing studies on respiratory syncytial virus (RSV) epidemiology, clinical presentation, and treatment modalities.
• Analysis of current clinical practices for managing severe RSV disease in pediatric and adult populations.
• Examination of emerging evidence on antiviral therapies, vaccines, and passive immunization strategies.

Main Results:

• Severe RSV disease management has benefited from non-invasive ventilation and high-flow oxygen, particularly in children.
• Refractory hypoxemia in severe cases often requires advanced support like mechanical ventilation or ECMO.
• Bacterial co-infections, though infrequent, are linked to poorer outcomes, posing diagnostic challenges and complicating antibiotic stewardship.

Conclusions:

• While supportive care remains central, advancements in ventilation and oxygenation have improved outcomes for severe RSV.
• Accurate diagnosis of bacterial co-infections is crucial but challenging, necessitating judicious antibiotic use.
• The future of RSV treatment hinges on the successful development and implementation of novel antiviral therapies, vaccines, and passive immunization strategies like nirsevimab.